{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T03:49:28Z","timestamp":1770781768743,"version":"3.50.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,10]]},"DOI":"10.7759\/cureus.103366","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:07:52Z","timestamp":1770750472000},"source":"Crossref","is-referenced-by-count":0,"title":["Generalized Pustular Psoriasis: Current Treatment and Innovative Therapies"],"prefix":"10.7759","author":[{"given":"Jos\u00e9 Dario","family":"Mart\u00ednez Villarreal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano","family":"Garcia-Campa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Hernandez-Fuentes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas Alberto","family":"C\u00e1rdenas-de la Garza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Martorell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.02.018","article-title":"Real-world clinical characteristics and treatment patterns of generalized pustular psoriasis flares","volume":"92","author":"Rhoads JL","year":"2025","unstructured":"Rhoads JL, Lavasani L, Rasouliyan L, Laouri M, Noe M. Real-world clinical characteristics and treatment patterns of generalized pustular psoriasis flares. J Am Acad Dermatol. 2025, 92:1243-51. 10.1016\/j.jaad.2025.02.018","journal-title":"J Am Acad Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18720","article-title":"Prevalence, comorbidities and mortality of generalized pustular psoriasis: A literature review","volume":"37","author":"Prinz JC","year":"2023","unstructured":"Prinz JC, Choon SE, Griffiths CE, Merola JF, Morita A, Ashcroft DM, Viguier M. Prevalence, comorbidities and mortality of generalized pustular psoriasis: A literature review. J Eur Acad Dermatol Venereol. 2023, 37:256-73. 10.1111\/jdv.18720","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2116003","article-title":"Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion","volume":"18","author":"Bachelez H","year":"2022","unstructured":"Bachelez H, Barker J, Burden AD, Navarini AA, Krueger JG. Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion. Expert Rev Clin Immunol. 2022, 18:1033-47. 10.1080\/1744666X.2022.2116003","journal-title":"Expert Rev Clin Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00881-0","article-title":"Generalized pustular psoriasis: a review on clinical characteristics, diagnosis, and treatment","volume":"13","author":"Rivera-D\u00edaz R","year":"2023","unstructured":"Rivera-D\u00edaz R, Daud\u00e9n E, Carrascosa JM, Cueva P, Puig L. Generalized pustular psoriasis: a review on clinical characteristics, diagnosis, and treatment. Dermatol Ther (Heidelb). 2023, 13:673-88. 10.1007\/s13555-022-00881-0","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llaf238","article-title":"Treatment with spesolimab in patients with generalized pustular psoriasis: a review of real-world experience","volume":"50","author":"Cardenas-de la Garza JA","year":"2025","unstructured":"Cardenas-de la Garza JA, Dominguez-Chapa E, Garza-Elizondo AK, et al.. Treatment with spesolimab in patients with generalized pustular psoriasis: a review of real-world experience. Clin Exp Dermatol. 2025, 50:1733-40. 10.1093\/ced\/llaf238","journal-title":"Clin Exp Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01801-4","article-title":"Spesolimab: first approval","volume":"82","author":"Blair HA","year":"2022","unstructured":"Blair HA. Spesolimab: first approval. Drugs. 2022, 82:1681-6. 10.1007\/s40265-022-01801-4","journal-title":"Drugs"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20966","article-title":"Prevalence and incidence of generalized pustular psoriasis in Sweden: a population-based register study","volume":"186","author":"L\u00f6fvendahl S","year":"2022","unstructured":"L\u00f6fvendahl S, Norlin JM, Schmitt-Egenolf M. Prevalence and incidence of generalized pustular psoriasis in Sweden: a population-based register study. Br J Dermatol. 2022, 186:970-6. 10.1111\/bjd.20966","journal-title":"Br J Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111563","article-title":"Trial of spesolimab for generalized pustular psoriasis","volume":"385","author":"Bachelez H","year":"2021","unstructured":"Bachelez H, Choon SE, Marrakchi S, et al.. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021, 385:2431-40. 10.1056\/NEJMoa2111563","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.02.040","article-title":"Rapid and sustained improvements in generalized pustular psoriasis physician global assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study","volume":"89","author":"Elewski BE","year":"2023","unstructured":"Elewski BE, Lebwohl MG, Anadkat MJ, et al.. Rapid and sustained improvements in generalized pustular psoriasis physician global assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study. J Am Acad Dermatol. 2023, 89:36-44. 10.1016\/j.jaad.2023.02.040","journal-title":"J Am Acad Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.05.034","article-title":"Spesolimab reduces inflammation in generalized pustular psoriasis: molecular characterization of flare treatment in Effisayil 1","volume":"145","author":"Farag A","year":"2025","unstructured":"Farag A, Visvanathan S, Bachelez H, et al.. Spesolimab reduces inflammation in generalized pustular psoriasis: molecular characterization of flare treatment in Effisayil 1. J Invest Dermatol. 2025, 145:573-82. 10.1016\/j.jid.2024.05.034","journal-title":"J Invest Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2017.04.026","article-title":"CARE guidelines for case reports: explanation and elaboration document","volume":"89","author":"Riley DS","year":"2017","unstructured":"Riley DS, Barber MS, Kienle GS, et al.. CARE guidelines for case reports: explanation and elaboration document. J Clin Epidemiol. 2017, 89:218-35. 10.1016\/j.jclinepi.2017.04.026","journal-title":"J Clin Epidemiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14386","article-title":"European consensus statement on phenotypes of pustular psoriasis","volume":"31","author":"Navarini AA","year":"2017","unstructured":"Navarini AA, Burden AD, Capon F, et al.. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017, 31:1792-9. 10.1111\/jdv.14386","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad389","article-title":"Spesolimab treatment in a patient with generalized pustular psoriasis: a case report with 12-month follow-up and literature review","volume":"49","author":"Cardenas-de la Garza JA","year":"2024","unstructured":"Cardenas-de la Garza JA, Zazueta-L\u00f3pez RM, Garza-Elizondo AK, Flores-Gutierrez DP, Welsh E. Spesolimab treatment in a patient with generalized pustular psoriasis: a case report with 12-month follow-up and literature review. Clin Exp Dermatol. 2024, 49:286-8. 10.1093\/ced\/llad389","journal-title":"Clin Exp Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s40560-023-00681-4","article-title":"The influence of steroid type on outcomes in patients with acute respiratory distress syndrome","volume":"11","author":"Yoshihro S","year":"2023","unstructured":"Yoshihro S, Taito S, Yatabe T. The influence of steroid type on outcomes in patients with acute respiratory distress syndrome. J Intensive Care. 2023, 11:32. 10.1186\/s40560-023-00681-4","journal-title":"J Intensive Care"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00658-9","article-title":"Treatment options and goals for patients with generalized pustular psoriasis","volume":"23","author":"Krueger J","year":"2022","unstructured":"Krueger J, Puig L, Tha\u00e7i D. Treatment options and goals for patients with generalized pustular psoriasis. Am J Clin Dermatol. 2022, 23:51-64. 10.1007\/s40257-021-00658-9","journal-title":"Am J Clin Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14765","article-title":"Current management of generalized pustular psoriasis","volume":"32","author":"Kodali N","year":"2023","unstructured":"Kodali N, Blanchard I, Kunamneni S, Lebwohl MG. Current management of generalized pustular psoriasis. Exp Dermatol. 2023, 32:1204-18. 10.1111\/exd.14765","journal-title":"Exp Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00779-3","article-title":"Acute generalized exanthematous pustulosis: clinical features, differential diagnosis, and management","volume":"24","author":"Parisi R","year":"2023","unstructured":"Parisi R, Shah H, Navarini AA, Muehleisen B, Ziv M, Shear NH, Dodiuk-Gad RP. Acute generalized exanthematous pustulosis: clinical features, differential diagnosis, and management. Am J Clin Dermatol. 2023, 24:557-75. 10.1007\/s40257-023-00779-3","journal-title":"Am J Clin Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/life13122341","article-title":"Role of silver nitrate spray for skin wound care in patients with toxic epidermal necrolysis: our experience in 4 patients","volume":"13","author":"Martinez JD","year":"2023","unstructured":"Martinez JD, Cardenas JA, Soria M, et al.. Role of silver nitrate spray for skin wound care in patients with toxic epidermal necrolysis: our experience in 4 patients. Life (Basel). 2023, 13:10.3390\/life13122341","journal-title":"Life (Basel)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2024.2309301","article-title":"Clinical advances in biological therapy for generalized pustular psoriasis: a review","volume":"24","author":"Hsieh CY","year":"2024","unstructured":"Hsieh CY, Tsai TF. Clinical advances in biological therapy for generalized pustular psoriasis: a review. Expert Opin Biol Ther. 2024, 24:37-50. 10.1080\/14712598.2024.2309301","journal-title":"Expert Opin Biol Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14294","article-title":"Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study","volume":"45","author":"Sano S","year":"2018","unstructured":"Sano S, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. J Dermatol. 2018, 45:529-39. 10.1111\/1346-8138.14294","journal-title":"J Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13306","article-title":"Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study","volume":"43","author":"Imafuku S","year":"2016","unstructured":"Imafuku S, Honma M, Okubo Y, et al.. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016, 43:1011-17. 10.1111\/1346-8138.13306","journal-title":"J Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00653-0","article-title":"Clinical disease measures in generalized pustular psoriasis","volume":"23","author":"Burden AD","year":"2022","unstructured":"Burden AD, Choon SE, Gottlieb AB, Navarini AA, Warren RB. Clinical disease measures in generalized pustular psoriasis. Am J Clin Dermatol. 2022, 23:39-50. 10.1007\/s40257-021-00653-0","journal-title":"Am J Clin Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18999","article-title":"Psychometric validation of the generalized pustular psoriasis physician global assessment (GPPGA) and generalized pustular psoriasis area and severity index (GPPASI)","volume":"37","author":"Burden AD","year":"2023","unstructured":"Burden AD, Bissonnette R, Lebwohl MG, et al.. Psychometric validation of the generalized pustular psoriasis physician global assessment (GPPGA) and generalized pustular psoriasis area and severity index (GPPASI). J Eur Acad Dermatol Venereol. 2023, 37:1327-35. 10.1111\/jdv.18999","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.01.014","article-title":"Assessing psoriasis severity: psychometric validation of overall physician global assessment","volume":"86","author":"Taliercio V","year":"2022","unstructured":"Taliercio V, Langner AU, Secrest AM, Duffin KC. Assessing psoriasis severity: psychometric validation of overall physician global assessment. J Am Acad Dermatol. 2022, 86:637-8. 10.1016\/j.jaad.2021.01.014","journal-title":"J Am Acad Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12106","article-title":"Psoriasis area severity index (PASI) and the dermatology life quality index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies","volume":"28","author":"Mattei PL","year":"2014","unstructured":"Mattei PL, Corey KC, Kimball AB. Psoriasis area severity index (PASI) and the dermatology life quality index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014, 28:333-7. 10.1111\/jdv.12106","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref26","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner J","year":"2007","unstructured":"Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007, 4:28-37.","journal-title":"Psychiatry (Edgmont)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19830","article-title":"Psychometric validation of the psoriasis symptom scale, functional assessment of chronic illness therapy-fatigue and pain-visual analogue scale in patients with generalized pustular psoriasis","volume":"38","author":"Burden AD","year":"2024","unstructured":"Burden AD, Bissonnette R, Anatchkova M, et al.. Psychometric validation of the psoriasis symptom scale, functional assessment of chronic illness therapy-fatigue and pain-visual analogue scale in patients with generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2024, 38:1383-90. 10.1111\/jdv.19830","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology life quality index (DLQI) - a simple practical measure for routine clinical use","volume":"19","author":"Finlay AY","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology life quality index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994, 19:210-16. 10.1111\/j.1365-2230.1994.tb01167.x","journal-title":"Clin Exp Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14824","article-title":"Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study","volume":"32","author":"Burden AD","year":"2023","unstructured":"Burden AD, Okubo Y, Zheng M, et al.. Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study. Exp Dermatol. 2023, 32:1279-83. 10.1111\/exd.14824","journal-title":"Exp Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01378-8","article-title":"Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial","volume":"402","author":"Morita A","year":"2023","unstructured":"Morita A, Strober B, Burden AD, et al.. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023, 402:1541-51. 10.1016\/S0140-6736(23)01378-8","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.09.080","article-title":"Generalized pustular psoriasis: a consensus statement from the National Psoriasis Foundation","volume":"90","author":"Armstrong AW","year":"2024","unstructured":"Armstrong AW, Elston CA, Elewski BE, Ferris LK, Gottlieb AB, Lebwohl MG. Generalized pustular psoriasis: a consensus statement from the National Psoriasis Foundation. J Am Acad Dermatol. 2024, 90:727-30. 10.1016\/j.jaad.2023.09.080","journal-title":"J Am Acad Dermatol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.24875\/GMM.24000403","article-title":"Classification and recommendations of the Mexican group for the study of psoriasis and other immune-mediated diseases (psomex) for the diagnosis and treatment of generalized pustular psoriasis. (Article in Spanish)","volume":"161","author":"Podoswa-Ozerkovsky N","year":"2025","unstructured":"Podoswa-Ozerkovsky N, Vega-Gonzalez LG, Amaya-Guerra M, et al.. Classification and recommendations of the Mexican group for the study of psoriasis and other immune-mediated diseases (psomex) for the diagnosis and treatment of generalized pustular psoriasis. (Article in Spanish). Gac Med Mex. 2025, 161:477-86. 10.24875\/GMM.24000403","journal-title":"Gac Med Mex"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15431","article-title":"Efficacy of glucagon-like peptide-1 receptor agonists for psoriasis: an updated systematic review and meta-analysis","volume":"22","author":"Ku SC","year":"2024","unstructured":"Ku SC, Chang HC. Efficacy of glucagon-like peptide-1 receptor agonists for psoriasis: an updated systematic review and meta-analysis. J Dtsch Dermatol Ges. 2024, 22:1148-52. 10.1111\/ddg.15431","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/457602-generalized-pustular-psoriasis-current-treatment-and-innovative-therapies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:07:53Z","timestamp":1770750473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/457602-generalized-pustular-psoriasis-current-treatment-and-innovative-therapies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.103366","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,10]]}}}